Brief: Neurosense's Primec Demonstrates Outstanding Effect On ALS Survival In Innovative IPSC Model

Neurosense Therapeutics

04/10/2023 14:13

Oct 4 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE'S PRIMEC DEMONSTRATES OUTSTANDING EFFECT ON ALS
SURVIVAL IN INNOVATIVE IPSC MODEL
    * NEUROSENSE THERAPEUTICS LTD - EXPECTS CLINICAL TOPLINE
RESULTS
FROM PARADIGM, ITS PHASE 2B STUDY OF PRIMEC IN TREATMENT OF ALS
IN Q4 OF 2023

Source text for Eikon:  ID:nPnb6X6Qda 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))